Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Celgene
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis and a psoriasis lesion
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID), compared with placebo, on the signs and symptoms of psoriatic arthritis (P...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER
•Phase 2a To determine the Maximal Tolerated Dose (MTD) of lenalidomide in combination with cetuximab in subjects with KRAS mutant metastatic CRC. •Phase 2b To determine the response rate in subjec...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Celgene International II Sàrl
Update Il y a 4 ans
A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body
The primary objectives of the study are: •To determine how the drug [14C]-RPC1063 moves through the body and how fast it is removed from the body •To assess the amount of radioactivity found in bloo...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Study To Compare The Benefit And Safety Of Luspatercept (ACE-536) Versus Placebo in subjects with lack of normal Red Blood Cells Requiring Transfusion due to myelodysplastic syndromes (MDS) with ring sideroblasts
To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring siderobl...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Safety study of oral azacitidine (CC-486) in patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes experiencing no symptom of the disease after stem cell transplantation
To determine the maximal tolerated dose (MTD) of oral azacitidine in subjects with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A clinical study to compare the effectiveness and safety of the combination of lenalidomide, melphalan and prednisone with placebo, melphalan and prednisone in newly diagnosed Multiple Myeloma patients who are 65 years or older
To determine the efficacy of lenalidomide plus melphalan and prednisone (MPR) compared to placebo plus melphalan and prednisone (MP) in subjects with newly diagnosed multiple myeloma (MM) who are 65 y...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis
To evaluate the 84-day clinical efficacy of 2 dose regimens of CC-10004 (20 mg per os [PO] twice per day [BID, total daily dose of 40 mg] or 40 mg PO once per day [QD], subsequent to a 7-day dose titr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 4 ans
Étude BB2121-MM-001 : étude de phase 2 évaluant l’efficacité et la tolérance de bb2121 chez des patients ayant un myélome multiple récidivant et réfractaire.
Le myélome multiple est une maladie de la moelle osseuse caractérisée par la multiplication dans la moelle osseuse d’un plasmocyte anormal. Le rôle des plasmocytes est de produire les anticorps (immun...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
,
Thérapie Cellulaire
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Celgene International Sàrl
Update Il y a 4 ans
A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA
To determine the time to progression (TTP) of previously treated subjects with multiple myeloma receiving lenalidomide
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to evaluate the efficacy and safety of Apremilast, Etanercept and placebo, in subjects with moderate to severe plaque psoriasis
To evaluate the clinical efficacy and safety of oral apremilast 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next